BCTX
BriaCell Therapeutics Corp.
NASDAQ · Healthcare · Biotechnology · CA
$3.57
+1.13%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -33.3%
- EBIT
- -12.7%
- EPS
- +71.7%
- Free cash flow
- -7.7%
- Operating cash flow
- -9.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- -13.2%
- Net income
- —
- EPS
- -45.5%
- Free cash flow
- -16.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Apr 1, 2026